UK-based clinical-stage biotechnology company TC BioPharm (Holdings) PLC (NASDAQ:TCBP) announced on Monday shareholder approval of a 25% stock dividend during its General Meeting.
The special dividend grants 0.25 American Depositary Shares (ADSs) for each ADS held on the record date of 2 January 2025, with delivery anticipated by 6 January 2025.
Trading in TC BioPharm's ADSs will pause at 17:00 hours on 2 January 2025, per Nasdaq requirements, resuming around 8 January 2025, to facilitate the dividend process. Nasdaq plans to adjust the opening price on 8 January to account for dilution from the dividend issuance.
Amgen announces Q1 2026 dividend
Eli Lilly announces Q1 2026 dividend
Amgen announces Q4 2025 dividend
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Perrigo to pay quarterly dividend of USD0.290 per share
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government
Fusion Antibodies secures multi-target humanisation contract with global pharmaceutical client
Genmab to acquire Merus in USD8bn deal to strengthen oncology pipeline
Wolters Kluwer launches UpToDate Expert AI to deliver trusted GenAI clinical decision support